

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q74854

Yoshinori SEKIGUCHI, et al.

Appln. No.: 10/551,431

Group Art Unit: 1614

Confirmation No.: 1607

Examiner: unknown

Filed: September 30, 2005

For: NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED  
TO THE USE THEREOF

**REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

**ATTN:** Office of Initial Patent Examination  
Filing Receipt Correction  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction:

**Assignment for Published Patent Application**

TAISHO PHARMACEUTICAL CO., LTD.

Verification for the requested correction is indicated on the Assignment filed August 24, 2006.

Respectfully submitted,

  
Susan J. Mack  
Registration No. 30,951

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

Date: December 11, 2006



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/551,431	08/24/2006	1614	4380	Q74854		57	1

## CONFIRMATION NO. 1607

23373  
 SUGHRUE MION, PLLC  
 2100 PENNSYLVANIA AVENUE, N.W.  
 SUITE 800  
 WASHINGTON, DC 20037

## FILING RECEIPT



\*OC000000020656307\*

Date Mailed: 10/03/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

Yoshinori Sekiguchi, Tokyo, JAPAN;  
 Kosuke Kanuma, Tokyo, JAPAN;  
 Katsunori Omodera, Tokyo, JAPAN;  
 Tsuyoshi Busujima, Tokyo, JAPAN;  
 Thuy-Anh Tran, San Diego, CA;  
 Sangdon Han, San Diego, CA;  
 Martin Casper, San Diego, CA;

Bryan A. Kramer, San Diego, CA;  
*Assignment for Published Patent Application*  
*TAISHO PHARMACEUTICAL CO, LTD.*

Power of Attorney: The patent practitioners associated with Customer Number 23373.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP04/04554 03/30/2004  
 which claims benefit of 60/458,424 03/31/2003

## Foreign Applications

If Required, Foreign Filing License Granted: 09/29/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/551,431**

Projected Publication Date: 01/11/2007

Non-Publication Request: No

**Early Publication Request: No**

**Title**

Novel quinazoline derivatives and methods of treatment related to the use thereof

**Preliminary Class**

514

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

## Assignment

Whereas, I/We, Yoshinori SEKIGUCHI; Kosuke KANUMA; Katsunori OMODERA; Tsuyoshi BUSUJIMA; Thuy-Anh TRAN; Sangdon HAN; Martin CASPER; Bryan A. KRAMER of hereinafter called assignor(s), have invented certain improvements in NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF and executed an application for Letters Patent of the United States of America therefor; and

Whereas, TAISHO PHARMACEUTICAL CO., LTD., Japan (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses (Application number 10/551,431 and Confirmation number 1607, filed September 30, 2005) the application number, confirmation number and filing date of said application when known.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

# ASSIGNMENT

(譲渡証)

IN CONSIDERATION of the sum of One Dollar (\$1.00) or the equivalent thereof, and other good and valuable consideration paid to Yoshinori SEKIGUCHI, Kosuke KANUMA, Katsunori OMODERA and Tsuyoshi BUSUJIMA, citizens of Japan, Thuy-Anh Tran, Martin CASPER and Bryan A. KRAMER, citizens of U.S.A., Sangdon Han, a citizen of the Republic of Korea, by TAISHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, located at 24-1, Takada-3-chome, Toshima-ku, Tokyo, Japan, and Arena Pharmaceuticals, Inc. a corporation organized under the laws of California, U.S.A. located at 6166 Nancy Ridge Drive, San Diego, CA 92121, U.S.A., respectively, receipt of which is hereby acknowledged, we, the said Yoshinori SEKIGUCHI, Kosuke KANUMA, Katsunori OMODERA, Tsuyoshi BUSUJIMA, Thuy-Anh Tran, Sangdon Han, Martin CASPER and Bryan A. KRAMER, do hereby sell and assign to said TAISHO PHARMACEUTICAL CO., LTD., and Arena Pharmaceuticals, Inc., their successors and assigns, all our right, title and interest, in and for the United States of America, in and to "NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF"

invented by us and described in the application for United States Letters Patent therefor, executed on even date herewith, and all United States Letters Patent which may be granted therefor, and all divisions, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by said TAISHO PHARMACEUTICAL CO., LTD., and Arena Pharmaceuticals, Inc., their successors, assigns or other legal representatives, to the full end of term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by us if this assignment and sale had not been made;

And we hereby agree to sign and execute any further documents or instruments which may be necessary, lawful, and proper in the prosecution of said above-named application or in the preparation and prosecution of any continuing, continuation-in-part, substitute, divisional, renewal, reviewed or reissue applications or in any amendment, extension, or interference proceedings, or otherwise to secure the title thereto in said assignee;

And we do hereby authorize and request the Commissioner of Patents to issue said Letters Patent to said TAISHO PHARMACEUTICAL CO., LTD., and Arena Pharmaceuticals, Inc.

Signed on the date(s) indicated aside signatures:

	INVENTOR (S) (発明者フルネームサイン)	Date Signed (署名日)	WITNESSES (立会人サイン)
1)	<u>Yoshinori Sekiguchi</u> Yoshinori SEKIGUCHI	September 2, 2005	<u>Keiko Virishi</u>
2)	<u>Kosuke Kanuma</u> Kosuke KANUMA	September 2, 2005	<u>Keiko Virishi</u>
3)	<u>Katsunori Omodera</u> Katsunori OMODERA	September 2, 2005	<u>Keiko Virishi</u>
4)	<u>Tsuyoshi Busujima</u> Tsuyoshi BUSUJIMA	September 2, 2005	<u>Keiko Virishi</u>
5)	<u>Thuy-Anh Tran</u> Thuy-Anh TRAN	Oct 21, 2005	<u>M. A. S.</u>
6)	<u>Sangdon Han</u> Sangdon HAN	Oct. 21, 2005	<u>M. A. S.</u>
7)	<u>Martin Casper</u> Martin CASPER	October 21, 2005	<u>M. A. S.</u>
8)	<u>Bryan A. Kramer</u> Bryan A. KRAMER	October 20, 2005	<u>M. A. S.</u>
9)			